EuroAPI gains on market debut after spin-off from Sanofi
Reuters
Published May 06, 2022 03:13AM ET
Updated May 06, 2022 07:01AM ET
By Ludwig Burger
(Reuters) - Shares in EuroAPI, the drug ingredients business spun off from Sanofi (NASDAQ:SNY), rose on their Paris stock market debut on Friday, defying a wider market decline.
EuroAPI traded at around 12.25 euros at 0915 GMT, valuing the contract manufacturer's equity at 1.15 billion euros ($1.21 billion) and up 2% from its reference price of 12 euros.
The stock premiered in choppy markets, with world stocks falling towards their lowest in over a year as investors anticipated more U.S. interest rate rises and worried about the hit to growth from China's zero-COVID policy.
The STOXX Europe 600 Health Care index was down 1.7%, while France's blue chip index was off 1.5%.
"What a remarkable day it is," said EuroAPI Chief Executive Karl Rotthier after ringing the opening bell in Paris.
"It's my birthday today, that's another good start," added Rotthier, who joined in early 2020 from Dutch pharma ingredients maker Centrient Holding.
Sanofi shareholders will receive one EuroAPI share for 23 shares held in the parent company.
Sanofi shares were down 0.2%, when adjusting for EuroAPI's separation and the payout of a 4.07 billion ordinary dividend.
Sanofi, which will keep a 30% stake, distributed 58% of EuroAPI's equity capital to Sanofi shareholders as a dividend in kind. The French state will acquire 12% in the new company, based on the average market price over the next 30 days.
The group joins rivals including Siegfried and Lonza as stand-alone ingredients and services suppliers to the drugs industry.
As an independent group, EuroAPI has said it will push to win over more of Sanofi's rivals as customers and expand in high-margin drug development services.
Pharma groups that, unlike Sanofi, continue to produce drug ingredients for other drugmakers include Pfizer (NYSE:PFE), Teva and family-owned Boehringer Ingelheim.
EuroAPI's flotation comes as the coronavirus pandemic and Russia's attack on Ukraine have heightened concerns in the European Union over the region's dependency on critical pharma ingredient imports.
Get The News You Want
($1 = 0.9471 euros)
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.